GlassScriptPhysician profile
Lisa E Heichberger
NPI 1730166430
$5,427.56
in general payments reported to CMS, 2019-2025
27 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $597 · 2021: $593 · 2022: $790 · 2023: $736 · 2024: $958 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $990.26 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $787.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $626.71 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.79 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $484.57 | 2019-2025 | |
| Lilly USA, LLC | $274.84 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $251.32 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $235.60 | 2023-2025 | |
| Horizon Therapeutics Plc | $181.39 | 2022-2023 | Krystexxa |
| Dexcom, INC. | $163.20 | 2023-2025 | Dexcom G6 Transmitter |
| Stryker Corporation | $148.92 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astellas Pharma US INC | $132.79 | 2023-2025 | Veozah |
| Genentech USA, INC. | $104.15 | 2020 | |
| Abbott Laboratories | $90.90 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $75.86 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $45.63 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $42.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $39.92 | 2019-2020 | |
| Hologic Sales and Service, LLC | $37.93 | 2021-2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $36.30 | 2021-2022 | |
| Exact Sciences Corporation | $33.57 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $31.27 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $30.09 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.59 | 2024 | Caplyta |
| Acadia Pharmaceuticals INC | $17.03 | 2025 | Nuplazid |
| Esperion Therapeutics, INC. | $16.69 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Heichberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.